Spore.Bio key facts
as of Oct 2026- Developer of a bacterial detection technology designed to develop technological tools to help the food and beverage industry.
- Spore.Bio is valued at approximately $60.6M as of Oct 2026 (last reported valuation).
- It has raised $31.7M; the latest was Early Stage VC ($22.9M) in Jan 2026.
- Notable investors include Plug and Play Tech Center, Kima Ventures, Entrepreneurs First, La French Tech, Phoenix Court — 23 tracked in total.
- Status: Privately Held (backing).
Spore.Bio's last reported valuation, Feb 2025. Nothing priced has surfaced since.
- ·The complete investor list: 23 names
- ·Watch Spore.Bio: the Monday email on marks, rounds and moves
Spore.Bio funding rounds
No funding rounds for Spore.Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Spore.Bio
23+Membership and data by Private Market View
Spore.Bio valuation
Spore.Bio's last reported valuation was $60.6 million in Feb 2025. No priced round, secondary trade or fund mark has surfaced since.
Spore.Bio investors
23 investors are on record for Spore.Bio, including Plug and Play Tech Center, Kima Ventures, Entrepreneurs First and La French Tech. By type, the record holds 5 venture capital firms and 1 angel investor.
About Spore.Bio
Developer of a bacterial detection technology designed to develop technological tools to help the food and beverage industry. The company offers a new generation of microbiological technologies directly usable on the shop floor, combining cutting-edge optical technology with advanced machine-learning models, enabling cosmetics and pharmaceutical factories to help factories manufacture safe products.
- Sector
- Business Products and Services (B2B)
- HQ
- Paris, France
- Founded
- 2022
- Employees
- 50
- Website
- spore.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.